Loading...
Two fundamentally different approaches to growth hormone optimization — and when to use each
Both CJC-1295/Ipamorelin and MK-677 (Ibutamoren) increase growth hormone levels. But they do it through fundamentally different mechanisms, produce different GH release patterns, and carry different risk profiles. Understanding these differences is essential for choosing the right approach — or deciding whether to combine them.
| CJC-1295 (with DAC) | GHRH analog — stimulates the pituitary to release GH in pulses, mimicking the body's natural rhythm. The DAC (Drug Affinity Complex) extends half-life to 6-8 days. |
| Ipamorelin | GHRP (Growth Hormone Releasing Peptide) — activates ghrelin receptors on the pituitary to amplify GH pulses. Highly selective — does not significantly raise cortisol or prolactin like other GHRPs. |
| CJC-1295 + Ipamorelin (stacked) | Synergistic — CJC-1295 provides the baseline GHRH signal, Ipamorelin amplifies each pulse. Together they produce 3-5x the GH release of either alone. |
| MK-677 (Ibutamoren) | Oral ghrelin receptor agonist — non-peptide small molecule. Creates sustained GH elevation (not pulsatile). Also raises IGF-1, appetite, and cortisol to a moderate degree. |
The critical difference: CJC-1295/Ipamorelin preserves the body's natural pulsatile GH release pattern. MK-677 creates a sustained elevation that can desensitize GH receptors over time and disrupt the negative feedback loop. Pulsatile release is how the body was designed to use GH.
| Appetite increase | CJC/Ipa: Minimal / MK-677: Significant (ghrelin activation) — can cause 500-1000+ cal/day increase in appetite |
| Water retention | CJC/Ipa: Mild / MK-677: Moderate-Severe — facial puffiness, joint stiffness, increased blood pressure in some users |
| Fasting glucose | CJC/Ipa: No significant change / MK-677: Can raise fasting glucose 10-20 mg/dL with chronic use — insulin resistance risk |
| Cortisol | CJC/Ipa: Ipamorelin does NOT raise cortisol (unlike GHRP-6) / MK-677: Modest cortisol elevation in some studies |
| Prolactin | CJC/Ipa: No change / MK-677: Slight elevation possible |
| Sleep quality | CJC/Ipa: Improved (deeper slow-wave sleep) / MK-677: Improved (same mechanism — GH peaks during sleep) |
| Numbness/tingling | Both: Possible at higher doses — indicates GH-driven fluid retention. Reduce dose if persistent. |
Dose
2mg per week
Frequency
Once or twice weekly (due to extended half-life)
Route
Subcutaneous injection
Mechanism: GHRH analog with Drug Affinity Complex for extended half-life. Stimulates pituitary GH release in natural pulsatile pattern.
Dose
200 — 300mcg per dose
Frequency
1-3 times daily (typically pre-bed for sleep optimization)
Route
Subcutaneous injection
Mechanism: Selective GHRP that amplifies GH pulses without raising cortisol or prolactin. Best used with CJC-1295 for synergistic effect.
Dose
10 — 25mg per day
Frequency
Once daily, typically pre-bed
Route
Oral (capsule or liquid)
Mechanism: Non-peptide ghrelin receptor agonist. Creates sustained GH and IGF-1 elevation. Oral convenience but non-pulsatile release pattern.
Some advanced users combine CJC-1295/Ipamorelin with low-dose MK-677 (10mg). The rationale is that MK-677 provides a sustained baseline IGF-1 elevation while the peptide stack handles pulsatile GH release. This is an experimental approach with limited formal data. If attempted, start MK-677 at the lowest effective dose (10mg) and monitor fasting glucose and insulin at 4-week intervals. The appetite increase from MK-677 may be counterproductive for body recomposition goals.
Essential labs for GH secretagogue protocols
The majority of practitioners in the peptide optimization space prefer CJC-1295/Ipamorelin over MK-677 for most goals. The pulsatile GH release pattern, cleaner side effect profile, and absence of metabolic risks make it the more physiological choice. MK-677's primary advantage — oral convenience — comes at the cost of appetite stimulation, water retention, and potential insulin resistance. For users who cannot tolerate injections, MK-677 at the lowest effective dose (10-15mg) with regular glucose monitoring is a reasonable alternative.
Log doses, monitor interactions, and optimize your stack with AI tools.
Open DoseCraftPharma-grade, third-party tested. Our preferred vendor for the DoseCraft community.
Shop Peptide PartnersThis article is for educational purposes only. Peptide regulations vary by jurisdiction. Always consult a licensed healthcare professional before starting any protocol.
Track your protocol with precision tools. Source pharma-grade compounds from a trusted vendor.
Build this protocol in 60 seconds. AI-powered dose logging, half-life tracking, and interaction checks.
Open Protocol BuilderPharma-grade, third-party tested peptides from our preferred vendor. Trusted by the community.
Shop Peptide PartnersTesamorelin is the only FDA-approved growth hormone releasing peptide. It induces natural GH pulsations that target visceral fat, support deep sleep, preserve muscle, and reduce the inflammatory bomb ticking in abdominal adipose tissue.
Read researchNAD+ is the fundamental currency of cellular energy and repair. Supplements like NMN are precursors that rely on conversion, while injectable NAD+ delivers the molecule directly. Combined with MOTS-C and SS-31, a complete mitochondrial restoration protocol emerges.
Read researchSleep is when growth hormone pulses, tissue repairs, DNA damage is fixed, and memories consolidate. DSIP (delta sleep-inducing peptide), glycine, and GH peptides form a stack that transforms sleep from passive rest into active biological restoration.
Read researchNot medical advice — educational only. DoseCraft is an information and personal tracking platform. We do not provide medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting any protocol. Affiliate links may be present — we only recommend vendors we trust.